Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PF-01367338

Known as: PARP1 Inhibitor PF-01367338 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Rucaparib camsylate (CO-338, AG-014699, PF-01367338) is a potent PARP-1, PARP-2, and PARP-3 inhibitor. Phase I and II studies… Expand
  • figure 1
  • table 1
  • figure 2
Highly Cited
2013
Highly Cited
2013
Purposepoly(ADP ribose) polymerase inhibition has been shown to potentiate the cytotoxicity of DNA damaging agents. A phase I… Expand
  • table 1
  • table 2
  • figure 1
  • figure 3
2013
2013
Poly (ADP-ribose) polymerase (PARP) inhibitors are an emerging class of potential anti-cancer therapeutics currently being… Expand
2011
2011
e13576 Background: PARP is a key enzyme involved in base-excision repair. Pre-clinically it has been shown that BRCA1/2 deficient… Expand
2011
2011
3104 Background: AG-014699 (PF-01367338) is an intravenous, potent, selective PARP-1 and 2 inhibitor (Ki = 1.4 nM). In pre… Expand
2011
2011
e13615 Background: PF-01367338 is a poly (ADP-ribose) polymerase (PARP) inhibitor. The phosphate salt of PF-01367338 (PF-01367338… Expand
2011
2011
e13552 Background: Within the past several years multiple PARP inhibitors have been entered into clinical trials, in a variety of… Expand
2011
2011
TPS130 Background: TNBC patients who do not achieve pathologic complete response (pCR) have an extremely high risk of disease… Expand
2011
2011
Background Based on recently reported I-SPY trial, TNBC patients who had residual disease category II or III had 2-year disease… Expand